Alpha Cognition (ACOG) Competitors

Alpha Cognition logo
$7.92 +0.09 (+1.15%)
Closing price 04:00 PM Eastern
Extended Trading
$8.03 +0.11 (+1.39%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ACOG vs. HELP, ZVRA, ACHV, OVID, and PHAT

Should you buy Alpha Cognition stock or one of its competitors? Alpha Cognition's main competitors and comparable companies include Cybin (HELP), Zevra Therapeutics (ZVRA), Achieve Life Sciences (ACHV), Ovid Therapeutics (OVID), and Phathom Pharmaceuticals (PHAT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Alpha Cognition compare to Cybin?

Cybin (NASDAQ:HELP) and Alpha Cognition (NASDAQ:ACOG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Alpha Cognition has higher revenue and earnings than Cybin. Alpha Cognition is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CybinN/AN/A-$148M-$3.02N/A
Alpha Cognition$10.22M16.88-$20.67M-$1.37N/A

In the previous week, Alpha Cognition had 8 more articles in the media than Cybin. MarketBeat recorded 18 mentions for Alpha Cognition and 10 mentions for Cybin. Cybin's average media sentiment score of 0.24 beat Alpha Cognition's score of 0.20 indicating that Cybin is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cybin
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alpha Cognition
1 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cybin has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.32, meaning that its share price is 132% more volatile than the broader market.

Cybin currently has a consensus price target of $47.33, indicating a potential upside of 557.41%. Alpha Cognition has a consensus price target of $18.20, indicating a potential upside of 129.80%. Given Cybin's higher probable upside, research analysts plainly believe Cybin is more favorable than Alpha Cognition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cybin
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Alpha Cognition
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

17.9% of Cybin shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 8.6% of Alpha Cognition shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cybin has a net margin of 0.00% compared to Alpha Cognition's net margin of -147.26%. Alpha Cognition's return on equity of -50.90% beat Cybin's return on equity.

Company Net Margins Return on Equity Return on Assets
CybinN/A -71.78% -64.81%
Alpha Cognition -147.26%-50.90%-41.23%

Summary

Cybin and Alpha Cognition tied by winning 7 of the 14 factors compared between the two stocks.

How does Alpha Cognition compare to Zevra Therapeutics?

Alpha Cognition (NASDAQ:ACOG) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

Zevra Therapeutics has higher revenue and earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alpha Cognition$10.22M16.88-$20.67M-$1.37N/A
Zevra Therapeutics$106.47M5.25$83.23M$1.197.90

Zevra Therapeutics has a net margin of 52.80% compared to Alpha Cognition's net margin of -147.26%. Zevra Therapeutics' return on equity of 54.64% beat Alpha Cognition's return on equity.

Company Net Margins Return on Equity Return on Assets
Alpha Cognition-147.26% -50.90% -41.23%
Zevra Therapeutics 52.80%54.64%37.84%

In the previous week, Alpha Cognition and Alpha Cognition both had 18 articles in the media. Alpha Cognition's average media sentiment score of 0.20 beat Zevra Therapeutics' score of -0.04 indicating that Alpha Cognition is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alpha Cognition
1 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Zevra Therapeutics
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Neutral

35.0% of Zevra Therapeutics shares are owned by institutional investors. 8.6% of Alpha Cognition shares are owned by insiders. Comparatively, 3.7% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Alpha Cognition has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

Alpha Cognition currently has a consensus target price of $18.20, suggesting a potential upside of 129.80%. Zevra Therapeutics has a consensus target price of $23.86, suggesting a potential upside of 153.80%. Given Zevra Therapeutics' higher probable upside, analysts clearly believe Zevra Therapeutics is more favorable than Alpha Cognition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alpha Cognition
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Zevra Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
3.00

Summary

Zevra Therapeutics beats Alpha Cognition on 11 of the 15 factors compared between the two stocks.

How does Alpha Cognition compare to Achieve Life Sciences?

Alpha Cognition (NASDAQ:ACOG) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

Achieve Life Sciences has a net margin of 0.00% compared to Alpha Cognition's net margin of -147.26%. Alpha Cognition's return on equity of -50.90% beat Achieve Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Alpha Cognition-147.26% -50.90% -41.23%
Achieve Life Sciences N/A -511.12%-82.35%

Alpha Cognition has higher revenue and earnings than Achieve Life Sciences. Alpha Cognition is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alpha Cognition$10.22M16.88-$20.67M-$1.37N/A
Achieve Life SciencesN/AN/A-$54.65M-$1.55N/A

Alpha Cognition has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.42, meaning that its stock price is 142% more volatile than the broader market.

In the previous week, Alpha Cognition had 17 more articles in the media than Achieve Life Sciences. MarketBeat recorded 18 mentions for Alpha Cognition and 1 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.93 beat Alpha Cognition's score of 0.20 indicating that Achieve Life Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alpha Cognition
1 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Achieve Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

33.5% of Achieve Life Sciences shares are held by institutional investors. 8.6% of Alpha Cognition shares are held by insiders. Comparatively, 1.8% of Achieve Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alpha Cognition presently has a consensus price target of $18.20, indicating a potential upside of 129.80%. Achieve Life Sciences has a consensus price target of $15.50, indicating a potential upside of 131.17%. Given Achieve Life Sciences' higher probable upside, analysts clearly believe Achieve Life Sciences is more favorable than Alpha Cognition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alpha Cognition
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Achieve Life Sciences
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.00

Summary

Achieve Life Sciences beats Alpha Cognition on 8 of the 15 factors compared between the two stocks.

How does Alpha Cognition compare to Ovid Therapeutics?

Ovid Therapeutics (NASDAQ:OVID) and Alpha Cognition (NASDAQ:ACOG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Ovid Therapeutics has higher earnings, but lower revenue than Alpha Cognition. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ovid Therapeutics$1.45M288.36-$17.41M-$0.24N/A
Alpha Cognition$10.22M16.88-$20.67M-$1.37N/A

72.2% of Ovid Therapeutics shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by company insiders. Comparatively, 8.6% of Alpha Cognition shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ovid Therapeutics has a net margin of 0.00% compared to Alpha Cognition's net margin of -147.26%. Ovid Therapeutics' return on equity of -23.38% beat Alpha Cognition's return on equity.

Company Net Margins Return on Equity Return on Assets
Ovid TherapeuticsN/A -23.38% -20.76%
Alpha Cognition -147.26%-50.90%-41.23%

In the previous week, Alpha Cognition had 14 more articles in the media than Ovid Therapeutics. MarketBeat recorded 18 mentions for Alpha Cognition and 4 mentions for Ovid Therapeutics. Alpha Cognition's average media sentiment score of 0.20 beat Ovid Therapeutics' score of -0.13 indicating that Alpha Cognition is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ovid Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
Alpha Cognition
1 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ovid Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.32, suggesting that its stock price is 132% more volatile than the broader market.

Ovid Therapeutics currently has a consensus price target of $6.13, indicating a potential upside of 175.90%. Alpha Cognition has a consensus price target of $18.20, indicating a potential upside of 129.80%. Given Ovid Therapeutics' higher possible upside, research analysts plainly believe Ovid Therapeutics is more favorable than Alpha Cognition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ovid Therapeutics
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.83
Alpha Cognition
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Ovid Therapeutics beats Alpha Cognition on 9 of the 16 factors compared between the two stocks.

How does Alpha Cognition compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Alpha Cognition (NASDAQ:ACOG) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Phathom Pharmaceuticals has a net margin of -30.19% compared to Alpha Cognition's net margin of -147.26%. Phathom Pharmaceuticals' return on equity of 0.00% beat Alpha Cognition's return on equity.

Company Net Margins Return on Equity Return on Assets
Phathom Pharmaceuticals-30.19% N/A -13.38%
Alpha Cognition -147.26%-50.90%-41.23%

In the previous week, Alpha Cognition had 18 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 18 mentions for Alpha Cognition and 0 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.82 beat Alpha Cognition's score of 0.20 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Phathom Pharmaceuticals Very Positive
Alpha Cognition Neutral

Alpha Cognition has lower revenue, but higher earnings than Phathom Pharmaceuticals. Alpha Cognition is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phathom Pharmaceuticals$175.11M2.55-$221.25M-$1.03N/A
Alpha Cognition$10.22M16.88-$20.67M-$1.37N/A

Phathom Pharmaceuticals currently has a consensus price target of $20.11, suggesting a potential upside of 265.66%. Alpha Cognition has a consensus price target of $18.20, suggesting a potential upside of 129.80%. Given Phathom Pharmaceuticals' higher possible upside, equities analysts clearly believe Phathom Pharmaceuticals is more favorable than Alpha Cognition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Phathom Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Alpha Cognition
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Phathom Pharmaceuticals has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market.

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of Alpha Cognition shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Phathom Pharmaceuticals beats Alpha Cognition on 12 of the 17 factors compared between the two stocks.

Get Alpha Cognition News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACOG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACOG vs. The Competition

MetricAlpha CognitionPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$172.50M$13.61B$7.74B$11.66B
Dividend YieldN/A2.58%2.46%4.42%
P/E Ratio-5.7829.4134.1729.85
Price / Sales16.887.028.485.62
Price / CashN/A15.7421.9322.50
Price / Book2.755.114.373.66
Net Income-$20.67M$2.88B$3.52B$392.27M
7 Day Performance-9.28%-4.11%-5.47%-4.72%
1 Month Performance-3.30%-5.09%-4.58%-7.14%
1 Year Performance34.24%-7.45%-1.79%-7.51%

Alpha Cognition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACOG
Alpha Cognition
3.134 of 5 stars
$7.92
+1.1%
$18.20
+129.8%
+31.8%$172.50M$10.22MN/A71
HELP
Cybin
4.3514 of 5 stars
$9.39
+3.5%
$47.33
+404.1%
N/A$749.40MN/AN/A100
ZVRA
Zevra Therapeutics
3.6953 of 5 stars
$11.85
-0.6%
$27.14
+129.1%
+4.2%$705.19M$106.47M9.9661
ACHV
Achieve Life Sciences
2.2744 of 5 stars
$6.71
-1.1%
$15.50
+131.2%
+53.1%$689.94MN/AN/A28
OVID
Ovid Therapeutics
2.3937 of 5 stars
$2.78
-0.7%
$6.00
+115.8%
+83.9%$542.93M$1.58MN/A23

Related Companies and Tools


This page (NASDAQ:ACOG) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners